Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: POLBF )

0.1180 UNCHANGED
Last Price Updated: 3:19 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about POLBF

< Previous 1 2 3 Next >
Poolbeg-led Consortium Awarded EUR 2.3m Grant
Via ACCESSWIRE
Poolbeg Pharma PLC Announces AI Programme Yields Novel RSV Drug Targets
Via ACCESSWIRE
Poolbeg Pharma PLC Announces CEO Share Purchase
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 US Patent update
Via ACCESSWIRE
Poolbeg Licence of Melioidosis Vaccine Candidate
Via ACCESSWIRE
Poolbeg Pharma PLC Announces HC Wainwright Global Investment Conference
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Appointment of Joint Broker
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB001 Human Challenge Clinical Trial To Commence
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Appointment of Joint Broker
LONDON, UK / ACCESSWIRE / July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light... 
From Poolbeg Pharma PLC
Via AccessWire
Poolbeg Pharma PLC Announces POLB001 Human Challenge Clinical Trial To Commence
Major milestone reached as POLB 001 human challenge clinical trial ready to commence 
From Poolbeg Pharma PLC
Via AccessWire
Poolbeg Pharma PLC Announces Project update for AI model of RSV data
OneThree Biotech completes build and optimisation of AI model for RSV data - results to come in H2 
From Poolbeg Pharma PLC
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Poolbeg Pharma PLC Announces US Patents Granted for POLB 001 and POLB 002
Further Expansion of IP Portfolio Enhancing Protection of Poolbeg's Growing Pipeline 
From Poolbeg Pharma PLC
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Poolbeg Pharma PLC - GMP Manufacturing Contract Signed
Update on POLB 001 Clinical Development GMP manufacturing contract signed ensuring ample supply of POLB 001 for clinical development and for use in investigating further potential disease indications... 
From Poolbeg Pharma PLC
Via AccessWire
Poolbeg Pharma PLC Announces Result of AGM
LONDON, UK / ACCESSWIRE / April 4, 2022 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'Company') a clinical stage infectious disease pharmaceutical company with a unique capital light... 
From Poolbeg Pharma PLC
Via AccessWire
Poolbeg Pharma PLC Announces POLB001 Update - Clinical Trial Agreement Signed
On track to commence LPS human challenge clinical trial in June 2022 LONDON, UK / ACCESSWIRE / March 31, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company') announces that it... 
From Poolbeg Pharma PLC
Via AccessWire
Poolbeg Pharma PLC Announces Commencement of Trading on US OTCQB Market
Poolbeg Pharma commences trading on OTCQB Market in the United States LONDON, UK / ACCESSWIRE / March 30, 2022 / Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical stage infectious... 
From Poolbeg Pharma PLC
Via AccessWire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.